CureDuchenne Ventures is pleased to share that one of our research investments, Code Bio, has announced that have secured $75 million in additional investments to advance their gene therapy programs […]
We’re thrilled to announce that researchers at Nationwide Children’s Hospital have documented the first-ever creation of full-length dystrophin in a human as a response to gene therapy. CureDuchenne has contributed […]
Lianna Orlando, PhD and Bradley Hodges, PhD Bring Scientific and Investment Expertise to Global Rare Disease Nonprofit’s Venture Philanthropy Team Newport Beach, Calif. – May 13, 2022 – CureDuchenne, a […]
Pfizer’s Global Clinical Lead for Rare Neurological Diseases, Beth Belluscio, MD-PhD, and Debra Miller, Founder and CEO of CureDuchenne, sat down to educate the Duchenne community on Pfizer’s CIFFREO Trial […]
Entrada Therapeutics announced encouraging new data on their exon 44 skipping program following their presentation at TIDES USA 2022. CureDuchenne provided funding to Entrada last year as part of their Series […]
Premier Wine Series Brought Together Most Acclaimed Napa Valley Vintners Under One Roof in Philadelphia to Benefit Global Nonprofit CureDuchenne NEWPORT BEACH Calif., April 27, 2022 – CureDuchenne, a leading […]
Pfizer’s Letter to the Duchenne Community We are pleased to share the good news that several regulatory authorities have approved the re-start of our Phase 3 ambulatory trial (CIFFREO) for […]
Today, Solid Biosciences announced a change to its corporate strategy to better align resources with goals to bring SGT-001 and SGT-003 to patients. Key Takeaways: Enrollment in IGNITE DMD, its […]
Registration Now Open for Three-Day National Conference in Orlando, Welcoming Attendees From Across the Globe Newport Beach, Calif. (March 25, 2022) – CureDuchenne, a leading global nonprofit focused on finding […]
